Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson
  • Patent number: 5854211
    Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. These peptide derivatives have the formula:A--B--C--D--E (--F).sub.pwherein A, B, C, D, E, F and p are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation as well as improved growth hormone releasing activity.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 29, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Behrend Friedrich Lundt, Henning Th.o slashed.gersen, Birgit Sehested Hansen
  • Patent number: 5854050
    Abstract: A DNA construct comprising a DNA sequence encoding an enzyme exhibiting protease activity, which DNA sequence comprises the DNA sequence shown in SEQ ID No. 1 or 2 or an analog of any of these sequences being at least 80% homologous to the DNA sequence shown in SEQ ID No. 1 or 2. The proteases encoded by the DNA sequences have an acid pH optimum.
    Type: Grant
    Filed: February 1, 1996
    Date of Patent: December 29, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
  • Patent number: 5853702
    Abstract: The present invention relates to polypeptides having mutanase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to oral cavity compositions and methods for degrading mutan.
    Type: Grant
    Filed: February 7, 1997
    Date of Patent: December 29, 1998
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Randy M. Berka, Stephan Christgau, Torben Halkier, Jeff Shuster, Claus Crone Fuglsang
  • Patent number: 5851233
    Abstract: The invention relates to a process for providing a bleached look in the color density of the surface of dyed fabric, especialy cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and a phenothiazine or phenoxazine enhancing agent represented by formula (I).
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: December 22, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Anders Hjelholt Pedersen, Jesper Vallentin Kierulff
  • Patent number: 5851811
    Abstract: It has surprisingly been found that peroxidase variants with an improved stability towards hydrogen peroxide may be prepared by recombinant DNA techniques. Accordingly, the present invention relates to a peroxidase variant with improved hydrogen peroxide stability, characterized by insertion, deletion or substitution of one or more amino acid residues located in or near the substrate channel of the parent peroxidase, near the heme group of the parent peroxidase or at or near the active site of the parent peroxidase.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: December 22, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Karen Gjesing Welinder, Morten Birket Andersen
  • Patent number: 5851992
    Abstract: A pharmaceutical formulation comprising a growth hormone and asparagine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. The formulation may be used to treat a patient with a disorder associated with growth hormone deficiency.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 22, 1998
    Assignee: Novo Nordisk A/S
    Inventor: Hans Holmegaaard S.o slashed.rensen
  • Patent number: 5849704
    Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 15, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
  • Patent number: 5849700
    Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 15, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
  • Patent number: 5847150
    Abstract: A solid phase method for the synthesis of a plurality of differently substituted 2-methylenethiazoles with a wide variety of side-chain substituents as compounds of potential therapeutic interest. The 2-methylenethiazoles are prepared by acylation of a substrate-bound primary or secondary amine with cyanoacetic acid and reaction of the resulting cyanoacetamide with an isothiocyanate in the presence of a base. Alkylation with an appropriate alkyl halide under acidic conditions yields differently substituted, support-bound 2-methylene-2,3-dihydrothiazoles. These may be screened on the substrate or cleaved from the substrate and then screened in solution. The efficient synthesis of a wide variety of 2-methylenethiazoles using automated synthesis technology of the present method makes these compounds attractive candidates for the generation and rapid screening of diverse thiazole-based libraries.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: December 8, 1998
    Assignee: Novo Nordisk A/S
    Inventor: Florencio Zaragoza Dorwald
  • Patent number: 5846788
    Abstract: A process for the manufacture of a lignocellulose-based product from a lignocellulosic material comprises treating the lignocellulosic material and a phenolic polysaccharide having substituents containing a phenolic hydroxy group with an enzyme capable of catalyzing the oxidation of phenolic groups in the presence of an oxidizing agent.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: December 8, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Lars Saaby Pedersen, Claus Felby
  • Patent number: 5846747
    Abstract: The present invention relates to a recombinant glucagon-like peptide-1 (GLP-1) receptor, to a DNA construct which comprises a DNA sequence encoding a GLP-1 receptor, to methods of screening for antagonists of GLP-1 activity, and to the use of the GLP-1 receptor for screening for antagonists of GLP-1 activity.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: December 8, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Bernard Thorens, Liselotte Bjerre Knudsen
  • Patent number: 5846968
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: December 8, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Tine Krogh J.o slashed.rgensen, Knud Erik Andersen, Henrik Sune Andersen, Rolf Hohlweg, Peter Madsen, Uffe Bang Olsen
  • Patent number: 5846801
    Abstract: A thermostable lipase has been isolated from Pseudomonas solanacearum SD709 (FERM BP-5358) which has a mass of 32 kD by SDS-PAGE, enzymatic activity in a pH range of about 4-12, a pH optimum of 6.5-9.5 and a temperature optimum of 80.degree.-90.degree. C.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: December 8, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Takashi Kotsuka, Keijitsu Tanaka, Kazunori Sakimoto
  • Patent number: 5843753
    Abstract: The present invention relates to a novel metalloprotease obtainable from a fungus having increased proteolytic activity. Additionally, the invention related to isolated nucleic acid fragments encoding said metalloprotease as well as vectors, DNA constructs, and recombinant host cells comprising said nucleic acid fragments.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 1, 1998
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Jeffrey R. Shuster, Mark Madden, Donna L. Moyer, Claus Fuglsang, Sven Branner
  • Patent number: 5843745
    Abstract: The present invention relates to isolated nucleic acid constructs containing a sequence encoding a Scytalidium laccase, and the laccase proteins encoded thereby.
    Type: Grant
    Filed: October 4, 1995
    Date of Patent: December 1, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Randy Michael Berka, Sheryl Ann Thompson, Feng Xu
  • Patent number: 5843720
    Abstract: The present invention relates to methods of constructing recombinant Bacillus strains encoding a polypeptide of interest, in which method a DNA construct comprising a DNA sequence encoding the polypeptide of interest is introduced into a recipient Bacillus cell by conjugation from a donor cell.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: December 1, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Martin Tangney, Christian Hansen, Poul Erik Pedersen, Per Lina Jorgensen, Steen Troels Jorgensen
  • Patent number: 5843702
    Abstract: The present invention relates to an expression system which comprises a phage-like bacteriocin("phibacin") or a mutant thereof, or a gene or mutant of a phibacin having a function in gene expression, such as a repressor gene, which is used to transform bacterial host for the producion of proteins, in particular in gram positive bacteria.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: December 1, 1998
    Assignee: Novo Nordisk A/S
    Inventors: David John McConnell, Kevin Martin Devine, Charles O'Kane
  • Patent number: 5840680
    Abstract: The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: November 24, 1998
    Assignee: Novo Nordisk A/S
    Inventor: Per Balschmidt
  • Patent number: 5840486
    Abstract: The present invention relates to a mutant DNA sequence encoding protein phosphatase 1 G-subunit, wherein a mutation of G to T occurs in the position of codon 905 of the coding sequence, a method of detecting a mutation in the gene encoding protein phosphatase 1 G-subunit, as well as a diagnostic composition and a test kit for use in the method.
    Type: Grant
    Filed: October 2, 1995
    Date of Patent: November 24, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Oluf Pedersen, Christian Bj.o slashed.rb.ae butted.k, Lars Hansen, Patricia Townsend Cohen
  • Patent number: 5840677
    Abstract: The invention relates to a detergent composition comprising an enzyme and a boronic acid or borinic acid derivative which acts as a stabilizer for the enzyme in detergent compositions. Specific boronic acid inhibiters include benzofuran substituted boronic acids.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: November 24, 1998
    Assignees: Novo Nordisk A/S, Borax Consolidated Ltd.
    Inventors: Lone Kierstein Nielsen, Allison Deane-Wray